Characteristics of treatment-related dermatological toxicity in colorectal carcinoma.

617 Background: The use of novel targeted therapies is becoming increasingly prevalent. This study aimed to determine how novel- targeted therapies have changed the profile of dermatological toxicity in patients being treated for colorectal carcinoma. Methods: Retrospective analysis was performed in a single institution for all patients presenting over a period of 4 weeks. Participants were followed up for the remainder of the study period. Patient charts were reviewed for previou incidences of dermatological toxicity. Toxicity was graded using the Common Toxicity Criteria version 3. Statistical analysis was performed using SPSS version 19. Results: A total of 45 patients receiving treatment for colorectal carcinoma were included in the final analyses. Twenty-nine of these received novel targeted therapy (NTT) including bevacizumab, cetuximab, capecitabine, and panitumumab. Sixteen participants received traditional chemotherapy. In total 79 toxicities were evaluated. Participants receiving NTT experienced...